CRC Research Update — May 25, 2026
Today's colorectal cancer research highlights
mrd
A collection of 6 issues
Practical guidance for integrating ctDNA testing into clinical care
Skip to content
The CRC Digest
Practical guidance for integrating ctDNA testing into clinical care
A narrative review summarizes evidence for ctDNA minimal residual disease testing in gastrointestinal cancers, with strongest data supporting use in resected stage II colon cancer. (Clinical and Translational Oncology)
This content is informational only and
CRC Research Update — May 12, 2026
Today's colorectal cancer research highlights
Circulating Tumor DNA Shows Promise for Predicting Colorectal Cancer Recurrence
Skip to content
The CRC Digest
Circulating Tumor DNA Shows Promise for Predicting Colorectal Cancer Recurrence
A review of current evidence suggests circulating tumor DNA has significant prognostic and predictive potential for detecting minimal residual disease and individualizing adjuvant therapy in colorectal cancer. (Klinická Onkologie)
This content is informational only
CRC Research Update — April 06, 2026
Today's colorectal cancer research highlights
ctDNA testing offers noninvasive approach to detect minimal residual disease after surgery
Skip to content
The CRC Digest
ctDNA testing offers noninvasive approach to detect minimal residual disease after surgery
Scoping review examines how circulating tumor DNA can guide adjuvant therapy decisions and surveillance strategies in resected CRC. (Journal of Gastrointestinal Surgery)
This content is informational only and does not constitute medical